Get In-depth Biotech Coverage with Timmerman Report.
15
May
2025
Genentech’s Bet on NC, GSK Buys Boston Liver Drug, & Septerna Entices Novo
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.